Skip to content
Peptide Atlas
All peptides

SNAP-8

Tier 3 · Reported use
Also known as Acetyl octapeptide-3 · Acetyl glutamyl heptapeptide-1

The strongest source tags present are Tier 1 (human clinical/RCT), but these largely concern the parent hexapeptide Argireline (Acetyl Hexapeptide-8) and treatment-duration observations rather than independent randomized trials of SNAP-8 itself. For SNAP-8 specifically, nearly all efficacy data derive from Lipotec/Lubrizol proprietary in-vitro and cosmetic testing. A 2025 review rated the evidence for topical facial-muscle synaptic inhibition as largely hypothetical, and some sources assert no independent peer-reviewed human trials of SNAP-8 exist. The tier is set to reflect the strongest tags present while noting this substantial limitation.

Half-life
Not recorded
Routes
Topical
Goals
Cosmetic / anti-aging skincare · Wrinkle reduction (topical)
Cost / mg
Not recorded

How it works

SNAP-8 is a lab-made cosmetic peptide, an extended version of Argireline, designed to relax the small facial muscles that create expression lines. It is proposed to imitate part of a natural protein (SNAP-25) involved in nerve signaling, competing with that protein so the nerve releases less of the chemical (acetylcholine) that tells muscles to contract. The idea is that softer muscle contractions mean shallower dynamic wrinkles like crow's feet and forehead lines. Unlike Botox, it is described as a reversible competitor that relaxes rather than paralyzes muscles, so effects are subtler and fade when you stop using it. A major open question is whether such a large molecule can actually penetrate skin deeply enough to reach nerves.

Overview

Overview

SNAP-8 (INCI: Acetyl Octapeptide-3 / Acetyl Glutamyl Heptapeptide-1; also listed by one source as acetyl glutamyl heptapeptide-3) is a synthetic acetylated octapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, molecular formula C41H70N16O16S and a molecular weight of approximately 1,075 Da (CAS 868844-74-0, PubChem CID 76283482).

It was developed by Lipotec S.A.U. (Barcelona, Spain), now part of Lubrizol Life Science (acquired by Lubrizol/Berkshire Hathaway in 2012), as a second-generation follow-up to Argireline (Acetyl Hexapeptide-8/-3). SNAP-8 elongates the Argireline hexapeptide by two additional C-terminal amino acids (alanine and aspartic acid), a modification intended to enhance binding affinity and anti-wrinkle activity.

Proposed Mechanism

SNAP-8 is proposed to mimic the N-terminal domain of SNAP-25 and act as a reversible competitive inhibitor of SNARE complex assembly. By competitively displacing endogenous SNAP-25, it is thought to reduce vesicular fusion and decrease acetylcholine release, relaxing the facial muscles that produce dynamic expression lines. Importantly, and unlike botulinum toxin, it does not cleave SNAP-25 or cause muscle paralysis — it is described as relaxing muscles without freezing them.

Intended Use

SNAP-8 targets dynamic wrinkles caused by repeated facial muscle contraction — glabellar lines, crow's feet, and forehead lines — with little direct effect on static wrinkles. It is used exclusively as a topical cosmetic ingredient and is not an injectable.

Efficacy Evidence

  • In manufacturer (Lipotec/Lubrizol) in-vivo cosmetic testing, a 10% SNAP-8 formulation applied twice daily for 28 days reduced periorbital wrinkle depth by up to approximately 63% (figures cited include 63.18% and 63.13%) versus vehicle/baseline.
  • Other reported figures include an average wrinkle-depth reduction of ~35% (max approaching 60% in some areas) after 28-30 days, ~38% at 28 days, and ~21% at 7 days.
  • SNAP-8 is reported to be about 30% more potent than Argireline in head-to-head cosmetic comparisons, and in vitro assays report it inhibits SNARE assembly roughly 2-3x more potently than Argireline on a molar basis.
  • Visible effects typically require 20-60 days of continuous use, with microtopography improvements measured at 20-day intervals; effects are temporary and reverse on discontinuation.

Important Caveats

The published efficacy base is limited primarily to Lipotec/Lubrizol proprietary testing rather than independent peer-reviewed randomized clinical trials. A 2025 comprehensive review concluded that evidence for inhibition of synaptic transmission in facial muscles via topical application remains limited and largely hypothetical, and some sources assert that no independent human clinical trials or peer-reviewed human data exist for SNAP-8 (contrasting with roughly 15 years of human data for Argireline). Independent estimates of real-world improvement (~10-20%) are considerably more modest than manufacturer figures (~30-63%).

Much of the direct mechanistic data (chromaffin-cell exocytosis, SNARE inhibition, blepharospasm exploration) concerns related peptides — SNAP-25-derived peptides and Acetyl Hexapeptide-8 (Argireline) — rather than the SNAP-8 octapeptide itself.

Skin penetration is a key open question: at ~1,075 Da, SNAP-8 is about 18.6% larger than Argireline (~889 Da) and far exceeds the ~500 Da threshold typically permitted by the skin barrier. Several sources question whether it can reach the neuromuscular junction without penetration enhancers, and Lipotec's own transepidermal flux studies reportedly show no penetration advantage over Argireline — even as some marketing describes it as 'designed to penetrate deeper.'

What the research shows

161 findings extracted from the 16 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 4 human trial findings, 10 human study findings, 3 in vitro findings, 21 expert opinion findings and 4 anecdotal findings.

  • human trialVisible reduction in wrinkle depth occurs by day 20–282

  • human trial10% formulation reduced wrinkle depth up to 30% after 30 days16

  • human trialTotal anti-wrinkle efficacy of 48.9% in the argireline group16

  • human trialRoughness parameters significantly decreased vs placebo16

  • human studyEffects are temporary and reverse upon discontinuation2

  • human studyIn vivo tests on human volunteers applying a cream containing 10 percent SNAP-8 reported a reduction in wrinkle depth by up to 63 percent over 28 days5

  • human studyOverall, the peptide reduces wrinkle depth by an average of approximately 35 percent, with maximal improvements approaching 60 percent in certain areas after 28–30 days of consistent application in topical studies5

  • human studyClinical trials show SNAP-8 reduced wrinkle depth by up to 63% after just 28 days of twice-daily application6

Show the remaining 34

  • human studySNAP-8 is approximately 30% more effective than its predecessor Argireline6

  • human studyIn clinical testing, SNAP-8 translated to wrinkle depth reductions of up to 63.18%6

  • human studyManufacturer-funded studies demonstrate 30-60% wrinkle depth reduction after 28 days of twice-daily 10% Snap-8 application10

  • human studyIndependent research finds more modest 10-20% improvements with significant individual variation10

  • human studyArgireline (Ac-EEMQRR-NH2) in a 10 percent oil-in-water emulsion reduced wrinkle depth by up to about 30 percent over 30 days in a small group of volunteers11

  • human studyA 28-day topical clinical study demonstrated wrinkle depth reductions of approximately 63% versus baseline13

  • in vitroup to ~63% reduction in wrinkle depth metrics after 28 days of twice-daily application of a 10% formulation12

  • in vitroapproximately 30% greater activity in cosmetic efficacy assays compared to Argireline (Acetyl Hexapeptide-3) in Lipotec/Lubrizol studies12

  • in vitroSNAP-8 is approximately 30% more potent than its parent compound Argireline in wrinkle reduction13

  • expert opinionMultiple in vitro and clinical studies confirm measurable wrinkle reduction3

  • expert opinionThe in vitro data are strong, and a body of clinical evidence has begun to accumulate in support of the compound's efficacy as a topical anti-ageing peptide3

  • expert opinionSnap 8 helps smooth out crow's feet, forehead lines, and other expression wrinkles by up to 63% in just 28 days of regular use4

  • expert opinionSnap 8 is approximately 30% more active than its parent peptide Argireline4

  • expert opinionSNAP-8 peptide when used regularly, can reduce wrinkle depth by up to 63% in some cases4

  • expert opinionSnap-8 can achieve up to a 38% reduction in wrinkle depth within 28 days of application4

  • expert opinionWhen using SNAP-8 over a 7 day period, wrinkles reduce by 21% and over a 28 day period they reduce by approximately 63%4

  • expert opinionSNAP 8 helped to reduce wrinkles surrounding the eyes by up to 63.13 percent4

  • expert opinionSNAP-8 is generally considered to be approximately 30 percent more active than Argireline (Acetyl Hexapeptide-3) in anti-wrinkle assays5

  • expert opinionPublished evidence is limited to in-vitro/cell SNARE studies and manufacturer-conducted cosmetic testing rather than peer-reviewed clinical trials7

  • expert opinionDirect mechanistic data specific to the SNAP-8 octapeptide itself remain limited7

  • expert opinionInjectable neurotoxin provides 90%+ wrinkle elimination through complete muscle paralysis for 3-4 months, whereas topical Snap-8 offers temporary subtle smoothing requiring continuous application with effects disappearing within days of discontinuation10

  • expert opinionSupplier data position SNAP-8 as somewhat more active than Argireline at matched concentrations11

  • expert opinionNo independent peer-reviewed RCTs published as of 2026; most evidence is from cosmetic ingredient supplier studies13

  • expert opinionNo one has ever published a study showing Snap-8 actually reduces wrinkles in a real person14

  • expert opinionZero clinical trials exist for Snap-814

  • expert opinionZero peer-reviewed human data exists for Snap-814

  • expert opinionArgireline has fifteen years of human data while Snap-8 has none14

  • expert opinionNo independent laboratory has tested Snap-8 in human subjects14

  • expert opinionThe published clinical evidence base is limited primarily to Lipotec/Lubrizol proprietary data15

  • expert opinionA 2025 comprehensive review concluded that evidence for the inhibition of synaptic transmission in facial muscles via topical application remains limited and largely hypothetical15

  • anecdotalManufacturer (Lipotec) reported in its own in-vivo cosmetic testing a reduction in periorbital wrinkle depth (figures around a ~63% relative reduction) over 28 days of twice-daily topical use of a 10% formulation versus vehicle7

  • anecdotalWidely repeated SNAP-8 figures of roughly 35 to 63 percent reduction in wrinkle severity around the eyes after about 28 days originate from the manufacturer's technical literature, not from independent, randomized, peer-reviewed clinical trials11

  • anecdotalManufacturer-sponsored studies report up to 63% wrinkle depth reduction with 10% SNAP-8 solution applied twice daily for 28 days15

  • anecdotalApproximately 30% greater potency than Argireline in head-to-head comparisons15

How it works

Based on 2 human trial findings, 2 animal findings, 5 in vitro findings, 36 expert opinion findings and 16 theoretical findings.

  • human trialAcetyl Hexapeptide-8 (AH8) is a competitive SNAP25 inhibitor1

  • human trialArgireline inhibits neurotransmitter release with potency similar to BoNT A16

  • animalA SNAP-25 C-terminal peptide blocked the slow, ATP-dependent docking step of catecholamine secretion in bovine chromaffin cells, causing accumulation of docked dense-core vesicles7

  • animalIn bovine chromaffin-cell models, SNAP-25-derived peptides were observed to inhibit the ATP-dependent docking component of regulated secretion, reducing stimulated catecholamine release7

  • in vitroIn cell-free and cell-based assays, peptides of this family reduce neurotransmitter release11

  • in vitroStudies in bovine chromaffin cells report dose-dependent inhibition of catecholamine release by acetyl octapeptide-311

  • in vitroSNAP-8 is approximately 30% more active than its parent compound Argireline13

  • in vitroIn lab dishes, Snap-8 works two to three times better than Argireline at blocking muscle signals14

Show the remaining 53

  • in vitroSnap-8 inhibits SNARE complex assembly two to three times more potently than Argireline on a molar basis in isolated cells14

  • expert opinionThis synthetic octapeptide inhibits neuromuscular signalling that causes repetitive facial muscle contractions, reducing the depth and appearance of expression lines3

  • expert opinionSnap-8 operates through a specific, well-characterised biological mechanism that targets the very origin of expression wrinkles at the level of neuromuscular signalling3

  • expert opinionSnap-8 has been shown in research settings to target neuromuscular inhibition through a pathway that is homologous to, but topically applicable and far less invasive than, the botulinum toxin approach3

  • expert opinionIt was designed as a direct extension and refinement of the hexapeptide acetyl hexapeptide-3 (commercially known as Argireline), adding two additional amino acid residues to enhance receptor binding specificity and overall biological potency3

  • expert opinionSnap-8's mechanism of action centres on the SNARE (Soluble NSF Attachment Protein REceptor) protein complex responsible for membrane fusion events including the fusion of synaptic vesicles with the presynaptic membrane3

  • expert opinionSnap 8 is the brand name for Acetyl Octapeptide-3, a chain of eight amino acids4

  • expert opinionSnap 8 peptides target the same protein complex (SNARE) as Botox but in a completely different way4

  • expert opinionUnlike Botox which completely blocks muscle movement, Snap 8 gently relaxes muscles without freezing them4

  • expert opinionSnap 8 has 8 amino acids while Argireline has 64

  • expert opinionSnap 8 functions by mimicking a fragment of the SNAP-25 protein, which plays a crucial role in neurotransmitter release4

  • expert opinionUnlike Botulinum Toxin (Botox), SNAP-8 does not cleave SNAP-25 or cause muscle paralysis5

  • expert opinionSNAP-8 works through the exact same biological mechanism as botulinum toxin injections, just topically and gradually6

  • expert opinionSNAP-8, also known by its INCI name Acetyl Glutamyl Heptapeptide-1, is a synthetic octapeptide — a chain of eight amino acids6

  • expert opinionSNAP-8 is designed to mimic a fragment of SNAP-25, a protein that plays a critical role in the release of neurotransmitters at nerve-muscle junctions6

  • expert opinionSNAP-8 works through a gentler version of this same mechanism — competing with SNAP-25 for position in the neurotransmitter release complex, partially reducing acetylcholine release6

  • expert opinionSNAP-8 competes with the natural SNAP-25 for a position in the SNARE complex — destabilizing it and reducing the efficiency of neurotransmitter release6

  • expert opinionSNAP-8 has additional two amino acids from the SNAP-25 sequence compared to Argireline, enhancing binding affinity to the SNARE complex6

  • expert opinionSNAP-8 is an elongated analog of Acetyl Hexapeptide-8 (Argireline), originally developed by Lipotec7

  • expert opinionSNAP-8 is reported to mimic the N-terminal domain of the SNAP-25 protein7

  • expert opinionSNAP-8 is a competitive mimic of the N-terminal end of SNAP-25, a component of the SNARE complex that mediates calcium-dependent fusion of neurotransmitter vesicles at the neuromuscular junction7

  • expert opinionSnap-8 (Acetyl Octapeptide-3) represents the next-generation evolution of Argireline (Acetyl Hexapeptide-8), featuring an extended eight-amino-acid chain designed to penetrate deeper and inhibit muscle contractions more effectively than its six-amino-acid predecessor10

  • expert opinionSNAP-8 belongs to a family of 'neurocosmetic' peptides designed to mimic part of a natural nerve-signaling protein11

  • expert opinionAcetyl Octapeptide-3 mimics the N-terminal sequence of SNAP-25 (synaptosomal-associated protein, 25 kDa) — a key component of the SNARE (Soluble NSF Attachment protein REceptor) complex required for synaptic vesicle fusion and acetylcholine exocytosis at the neuromuscular junction12

  • expert opinionBy competing with native SNAP-25 for SNARE complex assembly, Acetyl Octapeptide-3 attenuates acetylcholine release, reducing facial muscle contraction intensity and the resulting expression line formation12

  • expert opinionAcetyl Octapeptide-3 does not cleave proteins — it is a reversible competitive inhibitor, not an irreversible protease12

  • expert opinionthe two additional amino acids at the N-terminus improve SNAP-25 mimicry and enhance SNARE complex interference compared to the hexapeptide parent12

  • expert opinionSNAP-8 is an eight-amino-acid synthetic peptide and extended derivative of Argireline (Acetyl Hexapeptide-3)13

  • expert opinionSnap-8 is an octapeptide extension of Argireline designed to provide superior SNAP-25 inhibition14

  • expert opinionThe two extra amino acids in Snap-8 make the molecule bigger, and bigger molecules have a harder time getting through skin14

  • expert opinionSNAP-8 is a synthetic octapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 and a molecular weight of approximately 1,075 Da15

  • expert opinionSNAP-8 extends the original hexapeptide sequence by two additional C-terminal amino acids -- alanine and aspartic acid -- to enhance binding affinity and anti-wrinkle activity15

  • expert opinionSNAP-8 mimics the N-terminal domain of SNAP-25 and competitively inhibits SNARE complex assembly, thereby modulating acetylcholine release and attenuating the muscle contractions that create dynamic expression lines15

  • expert opinionFundamental questions persist regarding whether topically applied peptides of this molecular weight can penetrate to the neuromuscular junction in sufficient concentrations to meaningfully inhibit SNARE complex formation15

  • expert opinionSNAP-8 mimics the N-terminal end of SNAP-25 and competes with endogenous SNAP-25 for incorporation into the SNARE complex15

  • expert opinionSNAP-8 is approximately 30% more active than Argireline16

  • expert opinionSNARE complex inhibition confirmed as mechanism16

  • theoreticalSNAP-8 is an 8-amino acid SNARE inhibitor peptide2

  • theoreticalPrimary target is SNARE complex (SNAP-25 competitive binding site)2

  • theoreticalPathway: Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation2

  • theoreticalDownstream effect is transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction2

  • theoreticalSNAP-8 is a synthetic peptide derived from N-terminal fragment of SNAP-25 protein2

  • theoreticalSNAP-8 mechanism works by competitively mimicking the N-terminal end of the SNAP-25 protein, which interferes with the formation of the SNARE complex5

  • theoreticalThis action modulates neurotransmitter release and effectively attenuates (reduces) facial muscle contraction, leading to a visible reduction in expression lines and wrinkles5

  • theoreticalSNAP-8 is designed to mimic part of the SNAP-25 protein involved in neuromuscular signaling5

  • theoreticalBy competitively inhibiting SNAP-25 in the SNARE complex, SNAP-8 interferes with the final stages of neurotransmitter release5

  • theoreticalSNAP-8 effectively attenuates (reduces) acetylcholine release at neuromuscular junctions, thereby relaxing facial muscle contractions without causing paralysis5

  • theoreticalSNAP-8 mimics the N-terminal end of the endogenous SNAP-25 protein and competitively binds to the SNARE complex, displacing the natural SNAP-255

  • theoreticalSNAP-8 is proposed to destabilize SNARE assembly and thereby attenuate stimulated catecholamine/acetylcholine release7

  • theoreticalThe mechanism targets SNARE complex proteins controlling neurotransmitter release at neuromuscular junctions - by competing with SNAP-25 protein binding, Snap-8 theoretically reduces acetylcholine release that triggers muscle contractions10

  • theoreticalSNAP-8 mimics the N-terminal of SNAP-25 and competes for a place in the SNARE complex, modestly reducing neurotransmitter release11

  • theoreticalSNAP-8 mimics the N-terminal end of SNAP-25, a protein integral to the SNARE complex responsible for vesicular release of acetylcholine at the neuromuscular junction13

  • theoreticalBy competing with endogenous SNAP-25 for a position in the SNARE complex, SNAP-8 partially destabilizes complex formation13

Dosing

Based on 1 human trial finding, 2 human study findings, 1 in vitro finding, 7 expert opinion findings and 1 anecdotal finding.

  • human trialTreatment duration of 20–60 days required for visible effect with skin microtopography improvements measured at 20-day intervals2

  • human studyTypical concentration in cosmetic formulations is 2–10%, with commercial products typically using 5–10%2

  • human studyApplication frequency is twice daily (morning and evening)2

  • in vitroIn-vitro chromaffin-cell exocytosis assays used micromolar SNAP-25-derived peptide concentrations introduced intracellularly7

  • expert opinionMost effective serums contain a 3-10% concentration of SNAP-84

  • expert opinionApply a pea-sized amount of SNAP-8 peptide-containing products twice daily to areas prone to wrinkles4

  • expert opinionPharmaceutical-grade Snap-8 at proper concentrations (5-10%) in properly pH-buffered serums with penetration enhancers shows better results than diluted cosmetic formulations10

  • expert opinionEffective concentration range is 3-10% in finished formulation13

Show the remaining 4

  • expert opinionUse in serum applied after cleansing twice daily13

  • expert opinionSnap-8 is typically used in 3–5% solution, diluted to 0.5–1% in finished product14

  • expert opinionSNAP-8 is commercially available as SNAP-8 Peptide Solution C, a standardized solution containing 0.05% active peptide in water15

  • anecdotalTopical cosmetic emulsions formulated at roughly 3–10% of the supplier's peptide solution, applied to expression-line areas in manufacturer testing7

How the body handles it

Based on 2 in vitro findings, 4 expert opinion findings and 3 theoretical findings.

  • in vitroMethionine residue is susceptible to oxidation in formulation, which may reduce efficacy2

  • in vitroSystemic absorption is negligible; peptide remains in stratum corneum and epidermis2

  • expert opinionNo reliable human pharmacokinetic half-life for topical SNAP-8 has been established7

  • expert opinionSnap-8 is 18.6 percent larger than Argireline — 1,075 daltons versus 889 daltons14

  • expert opinionLipotec's own transepidermal flux studies show no penetration advantage for Snap-814

  • expert opinionSkin penetration remains a key challenge for topical delivery16

  • theoreticalFormulation types include oil-in-water emulsion, serum, cream2

  • theoreticalSnap-8 molecular weight of ~1075 Da is relatively large and skin barrier typically allows <500 Da, making penetration questionable without enhancers10

Show the remaining 1

  • theoreticalMethod applicable to microneedle patch delivery system analysis16

Safety and side effects

Based on 1 human trial finding, 2 human study findings, 1 in vitro finding, 12 expert opinion findings and 1 theoretical finding.

  • human trialNon-toxic peptide that emulates BoNT action through competitive inhibition16

  • human studySkin irritation is minimal and well-tolerated in clinical use2

  • human studyNo widespread allergic reactions reported2

  • in vitroConcentration-dependent antiproliferative effect observed in vitro with IC50 ~10 mg/mL for argireline (6-AA analogue)2

  • expert opinionRelative contraindications include active skin infections or open wounds at application site2

  • expert opinionSNAP-8 is not FDA-approved in the United States and is handled as a research compound2

  • expert opinionSuppliers describe topical use as well tolerated with no systemic neuromuscular effects reported7

  • expert opinionSNAP-8 is generally described as well tolerated as a topical cosmetic ingredient8

Show the remaining 9

  • expert opinionNo large-scale human safety trial exists for injected SNAP-89

  • expert opinionPeptide injection carries risks including infection, local irritation9

  • expert opinionPeptides are sensitive to light, heat, and pH and require proper formulation with preservatives and storage (refrigeration extends life)10

  • expert opinionSNAP-8 is a cosmetic ingredient (EU CosIng listed, used in US cosmetics), not an approved drug and not an injectable medicine11

  • expert opinionNo FDA-registered injectable compound application exists12

  • expert opinionConsidered safe for cosmetic use by EU regulatory assessments13

  • expert opinionMild skin irritation (rare), Transient redness13

  • expert opinionSNAP-8 is classified as a cosmetic ingredient (INCI: Acetyl Glutamyl Heptapeptide-1) and has not received drug approval in any regulatory jurisdiction15

  • theoreticalTheoretical concern exists for neuromuscular disorders with no documented cases2

What people use it for

Based on 1 human trial finding, 1 human study finding and 9 expert opinion findings.

  • human trialTopical Acetyl Hexapeptide-8 (AH8) was explored for safety and efficacy as a potential new therapy in BSP1

  • human studyApplication site is facial skin — glabellar lines, crow's feet, forehead2

  • expert opinionSnap 8 peptides can reduce expression lines by relaxing the facial muscles that cause wrinkles4

  • expert opinionSNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide originally developed as a cosmeceutical ingredient for anti-wrinkle effects5

  • expert opinionSNAP-8 is an extended analog of the well-known hexapeptide Argireline, designed to enhance anti-wrinkle efficacy5

  • expert opinionSNAP-8 targets dynamic wrinkles caused by repeated contraction of facial muscles6

  • expert opinionSNAP-8 has little direct effect on static wrinkles6

  • expert opinionSNAP-8 is a synthetic acetylated octapeptide (INCI Acetyl Octapeptide-3, also listed as Acetyl Glutamyl Heptapeptide-1) marketed as a topical cosmetic active for the appearance of expression lines7

Show the remaining 3

  • expert opinionSNAP-8 (acetyl octapeptide-3) is a synthetic peptide marketed for softening dynamic expression lines such as forehead creases and crow's feet11

  • expert opinionSNAP-8 is engineered to attenuate neuromuscular signaling that drives repetitive facial muscle contractions, reducing the appearance of expression lines and dynamic wrinkles13

  • expert opinionSnap-8 is not used as an injectable, only topical14

Other findings

Based on 8 expert opinion findings and 1 theoretical finding.

  • expert opinionSnap-8, formally known by its INCI name acetyl octapeptide-3 and also referred to as acetyl glutamyl heptapeptide-3, is a synthetic octapeptide developed by the Spanish cosmetic peptide company Lipotec3

  • expert opinionThe compound consists of eight amino acids in the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH23

  • expert opinionSNAP-8 is a cosmetic ingredient / research reagent and is not an approved therapeutic drug7

  • expert opinionSNAP-8 is the longer cousin of the better-known hexapeptide Argireline11

  • expert opinionSNAP-8 was developed by Lipotec in Spain, now part of Lubrizol Life Science, as a follow-up to Argireline11

  • expert opinionSNAP-8 sequence is Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH211

  • expert opinionthe published efficacy data for Acetyl Octapeptide-3 is primarily from Lipotec/Lubrizol-sponsored in vitro and controlled cosmetic studies rather than independent peer-reviewed pharmacology journals12

  • expert opinionSNAP-8 was developed by Lipotec S.A.U. (Barcelona, Spain; acquired by Lubrizol/Berkshire Hathaway in 2012) as a second-generation improvement of Argireline15

Show the remaining 1

  • theoreticalValidated LC-MS/MS method for acetyl octapeptide-3 quantification16

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Nearly all efficacy data come from the manufacturer, not independent peer-reviewed trials.

Multiple sources note the published evidence base is limited to Lipotec/Lubrizol proprietary in-vitro and cosmetic testing; a 2025 review called facial-muscle synaptic inhibition via topical application 'largely hypothetical', and evidence was rated Grade C strength. Independent randomized controlled trials for SNAP-8 are reported as absent.

Contested

Whether SNAP-8 can penetrate skin deeply enough to work is disputed.

SNAP-8 (~1,075 Da) far exceeds the ~500 Da skin-barrier threshold; SNAP-8 (Acetyl Octapeptide-3): Research Evidence & Safety Profile | PeptideInsight, Snap-8: Research, Evidence & Safety | Peptidings, SNAP-8 Research Studies and Evidence | Peptide Protocol Wiki and Snap-8 Peptide: Anti-Wrinkle Octapeptide Complete Guide - SeekPeptides question whether it reaches the neuromuscular junction, and Snap-8: Research, Evidence & Safety | Peptidings says Lipotec's own flux studies show no penetration advantage over Argireline. Meanwhile Snap-8 Peptide: Anti-Wrinkle Octapeptide Complete Guide - SeekPeptides markets it as 'designed to penetrate deeper' and Does Snap-8 reduce wrinkles - Peptides Lab UK claims a well-characterised, accumulating body of evidence — an unresolved tension.

Other

Direct mechanistic data are for related peptides, not SNAP-8 itself.

The chromaffin-cell exocytosis and SNARE inhibition data cited come from SNAP-25-derived/hexapeptide (Argireline) studies; SNAP-8 Dosage, Half-Life & Research | Peptigo explicitly notes that direct mechanistic data specific to the SNAP-8 octapeptide itself remain limited, and Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of .../SNAP-8 Research Studies and Evidence | Peptide Protocol Wiki evidence concerns Acetyl Hexapeptide-8 rather than SNAP-8.

Single source

Injectable-use safety statements come from isolated sources.

SNAP-8 Injection: How to Use, Dosing & What the ... alone notes no large-scale human safety trial exists for injected SNAP-8 and flags injection risks, while Snap-8: Research, Evidence & Safety | Peptidings states SNAP-8 is used only topically, never as an injectable; sources do not otherwise support injectable use.

Inconsistency

Overall tier 2 and the only tier-1 source (Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of ...) plus the 'human_rct' claim tags rest on Argireline data, not SNAP-8.

Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of ... (tier 1) is a pilot study of Acetyl Hexapeptide-8 (Argireline) in blepharospasm, and claims 34/35 tagged human_rct concern Argireline, not the octapeptide. The profile's own caveats state no independent RCTs or peer-reviewed human data exist for SNAP-8 and that mechanism is 'largely hypothetical.' Presenting a tier-1/RCT-grounded evidence posture for SNAP-8 overstates the actual SNAP-8 evidence base.

Inconsistency

Published figures for how much SNAP-8 a finished skincare product actually contains vary enormously, because some numbers describe the dilute peptide solution and others the tiny…

SNAP-8 is supplied to formulators as 'Peptide Solution C,' which is almost entirely water and contains only about 0.05% actual peptide. Products then incorporate this solution at roughly 3–10%. Doing the arithmetic, the pure peptide content of a finished cream or serum works out to only about 0.0015–0.005% — a few thousandths of a percent. One vendor-published source instead describes SNAP-8 as used at a '3–5% solution diluted to 0.5–1% in the finished product,' figures that are roughly 100 to 1,000 times higher; those almost certainly refer to the amount of peptide solution (or a differently defined concentrate) rather than pure peptide. The practical point for a reader is that the amount of actual peptide delivered is very small, and any single percentage figure is meaningless unless it states whether it refers to the peptide solution or to the pure peptide.

Inconsistency

Claim 20 is tagged human_rct but the source is a tier-3/2 web reference and the profile says no RCTs exist for SNAP-8.

A duration-of-effect statement from SNAP-8 — Dosage, Half-Life & Research Reference is labeled human_rct, directly contradicting the stated caveat that independent randomized controlled trials for SNAP-8 are absent. The evidence-type tag overstates the study design behind the claim.

What you may have heard

'Argireline... potency reported similar to botulinum toxin A' is a strong claim repeated from lower-tier sources.

Equating a topical hexapeptide's potency with injectable botulinum toxin A is a manufacturer-derived marketing framing not supported by controlled comparative data; even as a comparison point it risks importing an unsupported potency equivalence into the SNAP-8 narrative.

What you may have heard

'2–3x more potent than Argireline' rests on a single in-vitro source that elsewhere asserts no human data exist.

Claim 12 is sourced only to Snap-8: Research, Evidence & Safety | Peptidings, which simultaneously argues no human/clinical evidence for SNAP-8 exists. Presenting a precise molar-potency multiple alongside a 30% clinical-potency figure gives a false sense of quantitative certainty from divergent, low-tier data.

What you may have heard

Much of the clinical trial evidence cited for SNAP-8 is actually from studies of a different, related peptide called Argireline, not SNAP-8 itself.

The strongest human study linked to this peptide family — a pilot trial of topical Acetyl Hexapeptide-8 (Argireline) explored for blepharospasm — tested Argireline, the shorter parent peptide, rather than SNAP-8. No independent randomized controlled trials or peer-reviewed human efficacy studies of SNAP-8 itself have been published; the widely quoted wrinkle-reduction numbers come from the manufacturer's own cosmetic testing. Argireline has roughly fifteen years of human data behind it, while SNAP-8 has essentially none of its own, so any impression of a strong clinical evidence base for SNAP-8 largely borrows from work on the older peptide.

Using it with other compounds

Check a stack
  • SYN-AKEComplementary

    May be complementary

    Both soften dynamic wrinkles by quieting the neuromuscular junction, but from opposite sides of the synapse: SNAP-8 inhibits the presynaptic SNARE machinery that releases acetylcholine, whereas SYN-AKE blocks the postsynaptic nicotinic receptor that would receive it. Because they interrupt the same muscle-contraction signal at two different steps, combining them can give a more complete relaxation effect than either alone.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    The mechanism descriptions clearly establish that both peptides operate within the acetylcholine_pathway but at distinct anatomical locations: SNAP-8 targets presynaptic SNARE-mediated acetylcholine release (SNAP-25, SNARE complex, exocytosis), while SYN-AKE targets postsynaptic nicotinic acetylcholine receptors (mnAChR, alpha-1 subunit). Both produce muscle relaxation and wrinkle reduction through this shared pathway. The proposed relationship as 'complementary' with the shared dimension of 'acetylcholine_pathway' is directly supported by the mechanisms—they interrupt neuromuscular transmission at sequential steps (presynaptic release vs. postsynaptic reception), which justifies the claim that they could provide additive effects on muscle relaxation.

    Timing Topical use; can be layered in the same routine.

    Shares acetylcholine pathway

  • ArgirelineSame mechanism

    Worth caution

    SNAP-8 is essentially an extended version of Argireline — both are synthetic mimics of the SNAP-25 protein that competitively interfere with SNARE complex assembly to reduce acetylcholine release at facial muscles. Because they hit the exact same target by the same mechanism, layering both is redundant rather than additive; you are paying for two peptides doing one job. Choose one rather than stacking.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish the proposed relationship. Peptide A (Argireline) and Peptide B (SNAP-8) both: (1) target SNAP-25 and the SNARE complex, (2) operate via the same pathway (SNARE-mediated exocytosis and acetylcholine release at the neuromuscular junction), (3) share the approved tag 'acetylcholine_pathway', and (4) are explicitly described as synthetic mimics designed to interfere with the same natural protein machinery. The mechanism descriptions confirm they act on identical molecular targets through identical mechanisms. The explanation that SNAP-8 is 'an extended version of Argireline' and both competitively interfere with SNARE assembly to reduce acetylcholine release is directly supported by the provided mechanism material.

    Shares acetylcholine pathway

  • LeuphasylComplementary

    May be complementary

    SNAP-8 is an extended Argireline that blocks SNARE-complex assembly to reduce acetylcholine release, while Leuphasyl reduces the same release presynaptically through enkephalin/Gi signaling. Different molecular handles on the same neuromuscular relaxation goal, so they can complement each other in an anti-wrinkle topical rather than being redundant.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly target acetylcholine release reduction at the neuromuscular junction through distinct molecular pathways: Leuphasyl acts presynaptically via enkephalin receptor/Gi signaling and voltage-gated calcium channel inhibition (reducing calcium influx needed for exocytosis), while SNAP-8 acts by competitive inhibition of SNARE-complex assembly (blocking the final fusion machinery). These are mechanistically orthogonal approaches to the same endpoint (reduced acetylcholine release), which justifies the 'complementary' relationship type. Both are explicitly tagged with 'acetylcholine_pathway' and their mechanisms do not overlap or contradict—they represent different nodes in the same signaling cascade. The explanation accurately reflects the provided mechanism material.

    Timing Topical; apply together.

    Shares acetylcholine pathway

Safety and side effects

Safety & Tolerability

As a topical cosmetic ingredient, SNAP-8 is generally described as well tolerated. Reported skin irritation is minimal; mild irritation and transient redness are described as rare, and no widespread allergic reactions have been reported. Suppliers report no systemic neuromuscular effects from topical use.

Regulatory Status

SNAP-8 is classified as a cosmetic ingredient (EU CosIng listed, used in US cosmetics) and has not received drug approval in any jurisdiction. It is not FDA-approved, is handled as a research compound in that context, and has no FDA-registered injectable application. EU regulatory assessments considered it safe for cosmetic use.

Systemic Exposure

Systemic absorption of topical SNAP-8 is considered negligible, with the peptide reported to remain in the stratum corneum and epidermis; no reliable human pharmacokinetic half-life has been established.

Contraindications & Cautions

  • Relative contraindications include active skin infections or open wounds at the application site.
  • There is a theoretical (undocumented) concern for people with neuromuscular disorders.
  • Injectable use is not supported: one source notes no large-scale human safety trial exists for injected SNAP-8 and flags injection risks (infection, local irritation); another source states SNAP-8 is used only topically and never as an injectable.

Additional Notes

An in-vitro concentration-dependent antiproliferative effect was observed for the related hexapeptide argireline (IC50 ~10 mg/mL); this figure pertains to the 6-amino-acid analogue rather than SNAP-8 itself. An IC50 of ~10 mg/mL is an extremely high concentration — orders of magnitude beyond anything skin would encounter from a topical product — so it effectively indicates negligible cytotoxic relevance rather than a meaningful safety concern. Because much safety framing rests on manufacturer and expert-opinion sources rather than independent human trials, the overall human safety database specific to SNAP-8 remains limited.

Reconstitution and handling

Formulation & Concentration

SNAP-8 is a topical ingredient — not reconstituted for injection. It is commercially supplied as SNAP-8 Peptide Solution C, a standardized solution containing 0.05% active peptide in water.

  • In finished topical cosmetic formulations, the supplier's peptide solution is typically used at 3-10% (some sources cite 2-10%; commercial products commonly 5-10%).
  • One source describes typical use at 3-5% solution diluted to 0.5-1% in the finished product.
  • The pure peptide content of finished products is very low (roughly 0.0015-0.005%).
  • Applied to expression-line areas twice daily.

Formulation Types

Common vehicles include oil-in-water emulsions, serums, and creams.

Stability & Storage

  • Peptides are sensitive to light, heat, and pH and require proper formulation with preservatives and appropriate storage; refrigeration extends shelf life.
  • The methionine residue in SNAP-8 is susceptible to oxidation in formulation, which may reduce efficacy — a formulation stability consideration.

Duration of Use

Visible effects generally require about 20-60 days of continuous application, with wrinkle-depth reduction reported by day 20-28. Because effects are temporary and reverse upon discontinuation, continuous application is needed to maintain results.

Analytical Note

A validated LC-MS/MS method exists for acetyl octapeptide-3 quantification, applicable to microneedle patch delivery system analysis.

Sources

Ordered by evidence quality — the strongest first.

  1. Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  2. SNAP-8 — Dosage, Half-Life & Research Reference(opens in a new tab)
    Tier 2Web · peptidesdb.org
  3. Does Snap-8 reduce wrinkles - Peptides Lab UK(opens in a new tab)
    Tier 3Web · peptideslabuk.com
  4. How Snap 8 Peptides Reduce Expression Lines Fast(opens in a new tab)
    Tier 3Web · signalskinscience.com
  5. Snap-8(opens in a new tab)
    Tier 3Web · thepreptide.com
  6. SNAP-8 Before and After: Real Results & Clinical Evidence 2026 | I'm Fabulous Cosmetics(opens in a new tab)
    Tier 3Web · imfabulouscosmetics.com
  7. SNAP-8 Dosage, Half-Life & Research | Peptigo(opens in a new tab)
    Tier 3Web · peptigopeptides.com
  8. SNAP-8 Dosage: A Topical Anti-Wrinkle Peptide (2026)(opens in a new tab)
    Tier 3Web · thepeptidecatalog.com
  9. SNAP-8 Injection: How to Use, Dosing & What the ...(opens in a new tab)
    Tier 3Web · formblends.com
  10. Snap-8 Peptide: Anti-Wrinkle Octapeptide Complete Guide - SeekPeptides(opens in a new tab)
    Tier 3Web · seekpeptides.com
  11. SNAP-8 Peptide: Acetyl Octapeptide-3 Guide | PeptideStat(opens in a new tab)
    Tier 3Web · peptidestat.com · 2026
  12. Snap-8 (Acetyl Octapeptide-3): Complete Research Guide — SNARE Complex Inhibition, Neuromuscular Junction Biology & Cosmetic Efficacy Data (2026) - Your Peptide Brand(opens in a new tab)
    Tier 3Web · yourpeptidebrand.com · 2026
  13. SNAP-8 Peptide: Research, Dosage & Wrinkle Benefits(opens in a new tab)
    Tier 3Web · peptahub.com · 2026
  14. Snap-8: Research, Evidence & Safety | Peptidings(opens in a new tab)
    Tier 3Web · peptidings.com · 2026
  15. SNAP-8 (Acetyl Octapeptide-3): Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 3Web · peptideinsight.com · 2026
  16. SNAP-8 Research Studies and Evidence | Peptide Protocol Wiki(opens in a new tab)
    Tier 3Web · peptideprotocolwiki.com · 2026